Details for Patent: 8,486,941
✉ Email this page to a colleague
Which drugs does patent 8,486,941 protect, and when does it expire?
Patent 8,486,941 protects OJJAARA and is included in one NDA.
This patent has thirty-seven patent family members in twenty-two countries.
Summary for Patent: 8,486,941
| Title: | Phenyl amino pyrimidine compounds and uses thereof |
| Abstract: | The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. |
| Inventor(s): | Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng |
| Assignee: | GlaxoSmithKline LLC |
| Application Number: | US12/530,610 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Drugs Protected by US Patent 8,486,941
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-001 | Sep 15, 2023 | RX | Yes | No | 8,486,941 | ⤷ Start Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Start Trial | ||
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-002 | Sep 15, 2023 | RX | Yes | No | 8,486,941 | ⤷ Start Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Start Trial | ||
| Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | 8,486,941 | ⤷ Start Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,486,941
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008226327 | ⤷ Start Trial | |||
| Brazil | 122020010759 | ⤷ Start Trial | |||
| Brazil | PI0808888 | ⤷ Start Trial | |||
| Canada | 2702650 | ⤷ Start Trial | |||
| China | 101861313 | ⤷ Start Trial | |||
| China | 104030990 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
